Brief: Aditxt’S Adimune Program Has Initiated The Manufacturing Process Of Immunotherapeutic Drug Candidate Adi-100
21/10/2022 14:20
Oct 21 (Reuters) - Aditxt Inc ADTX.O :
* ADITXT’S (NASDAQ: ADTX) ADIMUNE™ PROGRAM HAS INITIATED THE
MANUFACTURING PROCESS OF IMMUNOTHERAPEUTIC DRUG CANDIDATE,
ADI™-100 IN PREPARATION FOR PLANNED PSORIASIS FIRST-IN-HUMAN
TRIALS
Source text for Eikon: ID:nBwbw1hp3a
Further company coverage: ADTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aditxt
See all newsBrief: Ignite Proteomics Announces 10,000-Patient Oncology Registry For Therapy Selection
Brief: Aditxt Appoints Jeffrey M. Busch As Interim CEO; Founder And Former CEO Of $1B NYSE Enterprise Which Delivered ~8.5% Dividends To Shareholders
NASDAQ TRADE HALT REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 03:28 AM